Gilead's Yeztugo beats forecasts as HIV PrEP franchise exceeds $1B
|
Gilead said its twice-yearly HIV prevention shot
Yeztugo generated $232 million in sales in the second quarter, topping Wall
Street estimates of ... |
BioNTech Launches mRNA HIV Vaccine Trial
... antiretroviral therapy for at least 12 months will receive four injections. Enrollment will span participants aged 18 to 50 years; those with HIV ... View article...